Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiation Therapy for High-Risk Prostate Cancer After Radical Prostatectomy
NCT03570827Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- May 2018
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Freedom From Failure at 5 years. Started May 2018; status: completed.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03570827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570827.